DIAAMOND
Avatrombopag plus up Front ImmunosuppReSsive untreated severe aplastic Therapy in naïve severe aplastic anaemia
Trial ID
ACTRN12619001042134
Cancer type
Aplastic anaemia
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Brief summary
The clinical trial will test if the treatment Avatrombopag in addition to standard immunosuppressive therapy (IST) is safe and will increase the rate of production of red blood cells, white blood cells and platelets in patients with aplastic anaemia. Avatrombopag is given in liquid form by injection into the vein.
Aplastic anaemia is a rare but serious disease, where the body stops producing enough new blood cells (red blood cells, white blood cells, and platelets). Avatrombopag works by helping the body to make more platelets, which help control clotting and prevent bleeding. It is hoped the combination of Avatrombopag given with IST will improve treatment outcomes.
The standard treatment for aplastic anaemia is IST and bone marrow transplantation. Treatment depends on the severity of the disease, patient age, and the availability of a suitable bone marrow donor.
Who can participate
Patients who:
- Have not been treated yet for aplastic anaemia
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australia New Zealand Clinical Trial Registry.